<p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家臨牀階段的生物技術公司，專注於基於其專有的 ADAPTIR™和 ADAPTIR-FLEX™平台技術開發新型免疫腫瘤治療藥物。今天宣佈將進行反向股票拆分，拆分比例為 1 比 18（&#34;反向股票拆分&#34;），針對其每股面值為 0.001 美元的普通股（&#34;普通股&#34;）。</p>
<p>反向股票拆分預計將於 12 月 29 日下午 5:01（東部時間）生效（&#34;生效時間&#34;），預計普通股將在 2025 年 12 月 30 日市場開盤時以拆分調整後的基礎在納斯達克資本市場開始交易。與反向股票拆分相關的，每 18 股截至生效時間已發行和流通的普通股將自動轉換為 1 股普通股。反向股票拆分不會改變普通股的交易代碼&#34;APVO&#34;。</p>
<p>反向股票拆分已獲得公司股東在 2025 年 7 月 24 日召開的年度股東大會（&#34;年度會議&#34;）上的批准，將在董事會的自由裁量權內在批准的參數內實施。年度會議後，最終比例於 2025 年 12 月 17 日獲得公司董事會的批准。</p>
<p>反向股票拆分將把已發行的普通股數量從約 1800 萬股（截至本新聞稿日期）減少到約 100 萬股，具體數量將根據四捨五入進行調整，並可能在反向股票拆分生效日期之前進行額外發行。</p>
<p>反向股票拆分將影響所有已發行和流通的普通股。所有未到期的期權、限制性股票單位、認股權證和其他證券的持有人在反向拆分後將根據每種證券的條款進行調整。根據公司的股權激勵計劃可授予的股份數量也將適當調整。反向拆分後，普通股的面值將保持不變，仍為每股 0.001 美元。反向股票拆分不會改變普通股或優先股的授權數量。與反向股票拆分相關的不會發行零碎股份，股東如有權獲得零碎股份，將有權獲得現金支付（不計利息）。</p>
<p>有關反向股票拆分的更多信息，請參閲公司於 2025 年 7 月 3 日向美國證券交易委員會（&#34;SEC&#34;）提交的最終代理聲明，以及公司計劃在生效時間後提交的 8-K 表格的當前報告。</p>
<p><strong>關於 Aptevo Therapeutics</strong></p>
<p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家臨牀階段的生物技術公司，專注於開發新型雙特異性和三特異性免疫療法用於癌症治療。公司目前有兩個臨牀候選藥物。Mipletamig 目前正在 RAINIER 進行評估，這是一個針對一線急性髓性白血病的兩部分 1b/2 期試驗，聯合標準治療 venetoclax + azacitidine。根據孤兒藥法，Mipletamig 已獲得急性髓性白血病的孤兒藥資格（&#34;孤兒狀態&#34;）。ALG.APV-527 是一種雙特異性條件性 4-1BB 激動劑，僅在同時結合 4-1BB 和 5T4 時活躍，正在與 Alligator Bioscience 共同開發，並最近在針對可能表達 5T4 的多種實體腫瘤類型的 1 期臨牀試驗中進行評估。公司還有六個具有不同作用機制的臨牀前候選藥物，旨在針對多種實體腫瘤。所有管線候選藥物均來自兩個專有平台，ADAPTIR 和 ADAPTIR-FLEX。Aptevo 的使命是改善治療結果，改變癌症患者的生活。有關更多信息，請訪問 www.aptevotherapeutics.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含 “前瞻性聲明”，包括管理層對公司未來預期、計劃和前景的看法，符合聯邦證券法下的安全港條款，包括 1995 年《私人證券訴訟改革法》。諸如 “期望”、“估計”、“預測”、“預算”、“展望”、“預期”、“打算”、“計劃”、“可能”、“將”、“能夠”、“應該”、“相信”、“預測”、“潛在”、“繼續” 等類似表達旨在識別此類前瞻性聲明。這些前瞻性聲明涉及重大風險和不確定性，可能導致實際結果與預期結果存在重大差異，因此，您不應將這些前瞻性聲明視為未來事件的預測。這些前瞻性聲明及可能導致此類差異的因素包括但不限於我們作為持續經營實體的能力；Aptevo 的業務或前景惡化；對初步或中期數據的進一步評估或後續臨牀試驗的不同結果；臨牀開發中的不良事件和意外問題及不利進展，包括在臨牀試驗中觀察到的意外安全問題；以及監管、社會、宏觀經濟和政治條件的變化。這些風險並非詳盡無遺，公司面臨已知和未知的風險。可能影響公司結果的其他風險和因素在公司向 SEC 提交的文件中列出，包括截至 2024 年 12 月 31 日的財政年度的 10-K 表格年度報告及其後續的 10-Q 表格和 8-K 表格當前報告。上述內容列出了許多但不是全部可能導致實際結果與公司在任何前瞻性聲明中的預期存在差異的因素。提醒讀者不要對任何前瞻性聲明過度依賴，包括但不限於關於實施反向股票拆分的聲明。這些報告和文件可在 www.sec.gov 上獲取，並在這些報告提交或提供給 SEC 後不久可在公司網站的 “投資者” 頁面 www.apvotherapeutics.com 上免費下載。任何前瞻性聲明僅在本新聞稿發佈之日有效，除法律要求外，公司不承擔更新任何前瞻性聲明以反映新信息、事件或情況的義務。</p>
<p><strong>聯繫方式：</strong></p>
<p>米里亞姆·韋伯·米勒</p>
<p>投資者關係與企業傳播負責人</p>
<p>Aptevo Therapeutics</p>
<p>電子郵件：<strong>IR@apvo.com</strong> 或 <strong>Millerm@apvo.com</strong></p>
<p>電話：206-859-6628</p>
<p><strong>來源：</strong> Aptevo Therapeutics</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMTIzMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMTIzMw"/></p>

APVO

<p>Aptevo Therapeutics Inc.（納斯達克代碼：APVO）宣佈將於 2025 年 12 月 29 日實施 1 比 18 的反向股票拆分。此次拆分將使流通股數量從 1800 萬股減少至 100 萬股。交易代碼 “APVO” 將保持不變。反向拆分已獲得股東和董事會的批准。不會發行零碎股份；將以現金支付代替。更多詳細信息請參見公司的 SEC 文件</p>

<p>Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will conduct a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (&#34;Common Stock&#34;), at a ratio of 1-for-18 (the &#34;Reverse Stock Split&#34;).</p>
<div class="lb-trans"><p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家臨牀階段的生物技術公司，專注於基於其專有的 ADAPTIR™和 ADAPTIR-FLEX™平台技術開發新型免疫腫瘤治療藥物。今天宣佈將進行反向股票拆分，拆分比例為 1 比 18（&#34;反向股票拆分&#34;），針對其每股面值為 0.001 美元的普通股（&#34;普通股&#34;）。</p>
</div><p>The Reverse Stock Split is expected to become effective on December 29, at 5:01 p.m. Eastern Time (the &#34;Effective Time&#34;), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted basis, at market open on December 30, 2025. In connection with the Reverse Stock Split, every 18 shares of Common Stock issued and outstanding as of the Effective Time will be automatically converted into one share of Common Stock. No change will be made to the trading symbol for the Common Stock, &#34;APVO,&#34; in connection with the Reverse Stock Split.</p>
<div class="lb-trans"><p>反向股票拆分預計將於 12 月 29 日下午 5:01（東部時間）生效（&#34;生效時間&#34;），預計普通股將在 2025 年 12 月 30 日市場開盤時以拆分調整後的基礎在納斯達克資本市場開始交易。與反向股票拆分相關的，每 18 股截至生效時間已發行和流通的普通股將自動轉換為 1 股普通股。反向股票拆分不會改變普通股的交易代碼&#34;APVO&#34;。</p>
</div><p>The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on July 24, 2025 (the &#34;Annual Meeting&#34;) to be effected in the Board's discretion within approved parameters. Following the Annual Meeting, the final ratio was approved by the Company's Board on December 17, 2025.</p>
<div class="lb-trans"><p>反向股票拆分已獲得公司股東在 2025 年 7 月 24 日召開的年度股東大會（&#34;年度會議&#34;）上的批准，將在董事會的自由裁量權內在批准的參數內實施。年度會議後，最終比例於 2025 年 12 月 17 日獲得公司董事會的批准。</p>
</div><p>The Reverse Stock Split will reduce the number of shares of outstanding Common Stock from approximately 18 million shares (as of the date of this press release) to approximately 1 million shares, subject to adjustment for rounding, as discussed below and potential additional issuances through the effective date of the Reverse Stock Split.</p>
<div class="lb-trans"><p>反向股票拆分將把已發行的普通股數量從約 1800 萬股（截至本新聞稿日期）減少到約 100 萬股，具體數量將根據四捨五入進行調整，並可能在反向股票拆分生效日期之前進行額外發行。</p>
</div><p>The Reverse Stock Split will affect all issued and outstanding shares of Common Stock. All outstanding options, restricted stock units, warrants, and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company's equity incentive plans will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.001 par value per share. The Reverse Stock Split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares will be issued in connection with the Reverse Stock Split, and stockholders who would otherwise be entitled to receive a fractional share of Common Stock will be entitled to receive a cash payment (without interest).</p>
<div class="lb-trans"><p>反向股票拆分將影響所有已發行和流通的普通股。所有未到期的期權、限制性股票單位、認股權證和其他證券的持有人在反向拆分後將根據每種證券的條款進行調整。根據公司的股權激勵計劃可授予的股份數量也將適當調整。反向拆分後，普通股的面值將保持不變，仍為每股 0.001 美元。反向股票拆分不會改變普通股或優先股的授權數量。與反向股票拆分相關的不會發行零碎股份，股東如有權獲得零碎股份，將有權獲得現金支付（不計利息）。</p>
</div><p>Additional information regarding the Reverse Stock Split is available in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (&#34;SEC&#34;) on July 3, 2025, and a Current Report on Form 8-K which the Company plans to file following the Effective Time.</p>
<div class="lb-trans"><p>有關反向股票拆分的更多信息，請參閲公司於 2025 年 7 月 3 日向美國證券交易委員會（&#34;SEC&#34;）提交的最終代理聲明，以及公司計劃在生效時間後提交的 8-K 表格的當前報告。</p>
</div><p><strong>About Aptevo Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Aptevo Therapeutics</strong></p>
</div><p>Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation (&#34;orphan status&#34;) for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and was most recently evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has six preclinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIRand ADAPTIR-FLEX. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.</p>
<div class="lb-trans"><p>Aptevo Therapeutics Inc. (NASDAQ:APVO) 是一家臨牀階段的生物技術公司，專注於開發新型雙特異性和三特異性免疫療法用於癌症治療。公司目前有兩個臨牀候選藥物。Mipletamig 目前正在 RAINIER 進行評估，這是一個針對一線急性髓性白血病的兩部分 1b/2 期試驗，聯合標準治療 venetoclax + azacitidine。根據孤兒藥法，Mipletamig 已獲得急性髓性白血病的孤兒藥資格（&#34;孤兒狀態&#34;）。ALG.APV-527 是一種雙特異性條件性 4-1BB 激動劑，僅在同時結合 4-1BB 和 5T4 時活躍，正在與 Alligator Bioscience 共同開發，並最近在針對可能表達 5T4 的多種實體腫瘤類型的 1 期臨牀試驗中進行評估。公司還有六個具有不同作用機制的臨牀前候選藥物，旨在針對多種實體腫瘤。所有管線候選藥物均來自兩個專有平台，ADAPTIR 和 ADAPTIR-FLEX。Aptevo 的使命是改善治療結果，改變癌症患者的生活。有關更多信息，請訪問 www.aptevotherapeutics.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes &#34;forward-looking statements&#34;, including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995. Words such as &#34;expect,&#34; &#34;estimate,&#34; &#34;project,&#34; &#34;budget,&#34; &#34;forecast,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;may,&#34; &#34;will,&#34; &#34;could,&#34; &#34;should,&#34; &#34;believes,&#34; &#34;predicts,&#34; &#34;potential,&#34; &#34;continue&#34; and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, our ability to continue as a going concern; a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems and adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. These risks are not exhaustive, the Company faces known and unknown risks. Additional risks and factors that may affect results of the Company are set forth in the Company's filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from the Company's expectations in any forward-looking statement. Readers are cautioned not to place undue reliance upon any forward-looking statements, including but not limited to statements about the effectuation of the Reverse Stock Split. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the &#34;Investors&#34; page of the Company's website at www.apvotherapeutics.com. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, the Company does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.</p>
<div class="lb-trans"><p>本新聞稿包含 “前瞻性聲明”，包括管理層對公司未來預期、計劃和前景的看法，符合聯邦證券法下的安全港條款，包括 1995 年《私人證券訴訟改革法》。諸如 “期望”、“估計”、“預測”、“預算”、“展望”、“預期”、“打算”、“計劃”、“可能”、“將”、“能夠”、“應該”、“相信”、“預測”、“潛在”、“繼續” 等類似表達旨在識別此類前瞻性聲明。這些前瞻性聲明涉及重大風險和不確定性，可能導致實際結果與預期結果存在重大差異，因此，您不應將這些前瞻性聲明視為未來事件的預測。這些前瞻性聲明及可能導致此類差異的因素包括但不限於我們作為持續經營實體的能力；Aptevo 的業務或前景惡化；對初步或中期數據的進一步評估或後續臨牀試驗的不同結果；臨牀開發中的不良事件和意外問題及不利進展，包括在臨牀試驗中觀察到的意外安全問題；以及監管、社會、宏觀經濟和政治條件的變化。這些風險並非詳盡無遺，公司面臨已知和未知的風險。可能影響公司結果的其他風險和因素在公司向 SEC 提交的文件中列出，包括截至 2024 年 12 月 31 日的財政年度的 10-K 表格年度報告及其後續的 10-Q 表格和 8-K 表格當前報告。上述內容列出了許多但不是全部可能導致實際結果與公司在任何前瞻性聲明中的預期存在差異的因素。提醒讀者不要對任何前瞻性聲明過度依賴，包括但不限於關於實施反向股票拆分的聲明。這些報告和文件可在 www.sec.gov 上獲取，並在這些報告提交或提供給 SEC 後不久可在公司網站的 “投資者” 頁面 www.apvotherapeutics.com 上免費下載。任何前瞻性聲明僅在本新聞稿發佈之日有效，除法律要求外，公司不承擔更新任何前瞻性聲明以反映新信息、事件或情況的義務。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Miriam Weber Miller</p>
<div class="lb-trans"><p>米里亞姆·韋伯·米勒</p>
</div><p>Head, Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>投資者關係與企業傳播負責人</p>
</div><p>Aptevo Therapeutics</p>
<div class="lb-trans"><p>Aptevo Therapeutics</p>
</div><p>Email: <strong>IR@apvo.com</strong> or <strong>Millerm@apvo.com</strong></p>
<div class="lb-trans"><p>電子郵件：<strong>IR@apvo.com</strong> 或 <strong>Millerm@apvo.com</strong></p>
</div><p>Phone: 206-859-6628</p>
<div class="lb-trans"><p>電話：206-859-6628</p>
</div><p><strong>SOURCE:</strong> Aptevo Therapeutics</p>
<div class="lb-trans"><p><strong>來源：</strong> Aptevo Therapeutics</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMTIzMw" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1121233"/></p>

Aptevo Therapeutics 宣佈進行 1 比 18 的反向股票拆分 | APVO 股票新聞